Information Hub

Clinical News

2018-03-31

A new ERK1/2 inhibitor showed clinical activity in patients with NRAS and BRAF-mutant solid tumors.

In a multicenter phase I trial (NCT01781429), patients with NRAS, BRAF or MEK-mutated advanced solid tumor were treated with ulixertinib, an ERK1/2 inhibitor, to identify its safeness and clinical activity. The results demonstrated that ulixertinib was we

Source:

Sullivan RJ, Infante JR, Janku F, et al. Cancer Discov. 2018;8(2):184-195.

2018-03-31

Cases on genetic information-guided treatment in patients with less common ERBB2 mutations

The authors report two cases with the less common ERBB2 transmembrane domain (TMD) mutation. They were treated with afatinib and were confirmed achieving clinical benefits. There are other cases with the less common ERBB2 mutation as reported in The Cance

Source:

Yamamoto H, Toyooka S, Ninomiya T, et al. Oncologist. 2018;23(2):150-154

2018-03-31

ctDNA could predict the treatment response of palbociclib and fulvestrant for breast cancer patients

In a phase III (PALOMA-3) study, clinical activity of palbociclib plus fulvestrant was confirmed in advanced hormone receptor-positive, HER2-negative breast cancer patients whose tumor had previously progressed on endocrine treatment. In this study, the a

Source:

O'Leary B, Hrebien S, Morden JP, et al. Nat Commun. 2018, 1;9(1):896.

2018-03-31

New data from a phase IIa trial revealed the potential of the targeted therapy across tumor types on the basis of molecular profiles

In the phase IIa (MyPathway) study, the patients with different advanced solid tumors harboring Her2, BRAF, EGFR or Hedgehog pathway alterations were treated with matching but are outside labeling targeted therapy. The results evaluated the efficacy of th

Source:

Hainsworth JD, Meric-Bernstam F, Swanton C, et al. J Clin Oncol. 2018, 20;36(6):536-542.

2018-03-31

Early-onset hereditary ovarian cancer may be an X-linked model

From 892 grandmother-granddaughter pairs of familial ovarian cancer samples, researchers found that the early-onset hereditary ovarian cancer gene may be located near the MAGEC3 gene on the X chromosome, and the male relatives with this mutation also have

Source:

Eng KH, Szender JB, Etter JL, et al. PLoS Genet. 2018, 15;14(2):e1007194

2018-03-01

Erdafitinib may show clinical activity in urothelial cancer with FGFR alterations

Based on the results of a phase II trial, erdafitinib, a pan-FGFR inhibitor, exhibited response in urothelial cancer patients who have progressed after standard chemotherapy with FGFR alterations.

Source:

Onclive

2018-03-01

Genomic profiling can help rare cancer patients find genotype-matched therapy

Based on the study by University of California-San Diego Moores Cancer Center, genotype-matched therapy showed clinical benefit in rare cancer patients via genomic testing.

Source:

The Oncologist

2018-03-01

Large pedigree exome analysis showed mutations in USP45 and ARID1A are associated with multiple myeloma

Researchers performed large pedigree exome analysis and confirmed that mutations in USP45 and ARID1A are associated with multiple myeloma.

Source:

Genome Web

2018-03-01

Entrectinib, a potential targeted therapy for metastatic pancreatic cancer

The mainstay of treatments for metastatic pancreatic cancer is chemotherapy. A new targeted drug, entrectinib, shows the clinical benefit for metastatic pancreatic cancer with NTRK and ROS1 fusion.

Source:

J Clin Oncol 36, 2018 (suppl 4S; abstr 521)

2018-03-01

A combination therapy shows clinical benefit in BRAF V600E-mutated anaplastic thyroid cancer

In a phase II trial, patients with BRAF V600E-mutated anaplastic thyroid cancer were treated with the dabrafenib and trametinib combination therapy, resulting in clinical benefit and manageable toxicity.

Source:

J Clin Oncol, 2018 Jan 1;36(1):7-13 doi: 10.1200/JCO.2017.73.6785.